$SYK

Fletcher Robert S sold $80K of SYK

Fletcher Robert S (VP, Chief Legal Officer) sold 258 shares of STRYKER CORP (SYK) at $308.78 on 2026-05-28 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Fletcher Robert S
Published May 29, 2026, 8:59 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 29, 2026, 9:02 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SYK
Neutral
high confidence
Mentioned
$SYK
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SYKNeutralLow
01

Why it matters

Because the plan is pre-arranged, the disclosure is usually informational for tracking insider activity, not a standalone fundamental trigger.

02

Market read

Routine insider sale disclosure; no new earnings, deal, litigation, or regulatory catalyst is mentioned.

03

What to watch

10b5-1 plans can mask timing; traders should check whether this sale is part of a larger, recurring schedule rather than treating it as new information.

Relevance 6/10Novelty 3/10Timing: Filed today; reflects a sale executed on 2026-05-28.

Background

SEC Form 4 reports insider transactions; this one is an open-market sale executed under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$SYKNeutralHigh confidence
Context

Stryker disclosed an officer open-market sale of 258 shares at ~$308.79 under a pre-arranged 10b5-1 plan.

Expected impact

Limited near-term impact; any effect is likely noise unless follow-on filings show unusual selling patterns.

Evidence & confidence

The filing is a routine, pre-arranged sale by a legal officer; no new company-specific operational or financial information is provided.

Market effects

No clear sector read-through; single-company insider transaction without new guidance or regulatory developments.

None indicated.

None indicated.

Counterpoint

If the officer’s selling accelerates across multiple consecutive filings, it could reflect personal liquidity needs rather than a fundamental view—still not a direct catalyst.

Key entities

  • STRYKER CORP

    Subject of the Form 4 insider sale disclosure.

  • Fletcher Robert S

    VP, Chief Legal Officer who sold 258 shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SYKHighAI 8/10

Stryker (NYSE: SYK) Scrutinized Amid Disclosure of Persisting Peripheral Vascular Problems -- HBSS

Stryker (SYK) shares fell $26.70 (-8.8%) on Sept. 8, 2026, after its CFO revealed persisting manufacturing issues in its Peripheral Vascular unit, acquired from Inari Medical. The firm Hagens Berman is investigating potential disclosure violations. The issue, initially thought resolved, led to lost sales and backorders, with the CFO stating it will continue into Q4.

$SYKLow

Why Stryker (SYK) Stock Is Down Today

Stryker (SYK) shares fell 6.9% after management at a healthcare conference indicated longer-than-expected supply chain issues and slower joint replacement recovery, potentially affecting revenue. The company had reported solid Q2 results in July. Insider sales and mixed hedge fund activity were also noted.

$SYKMed

Stryker stock drops 7.7% as supply problems and weak joint replacement sales hit outlook

Stryker shares dropped 7.7% on Tuesday due to ongoing supply chain issues and weaker-than-expected joint replacement sales. CFO Preston Wells stated that manufacturing problems will persist into Q4, impacting sales growth. The company also missed recovery expectations in its joint replacement business, citing seasonal weakness. Investors are concerned about the timing of a broader recovery.